Presentations

All presentations will be held in the Hawai’i Convention Center. All times are Hawaii Standard Time.

Wednesday, Feb. 12

John DiPersio, MD, PhD
Joint Session of the ASTCT and American Society of Gene & Cell Therapy (ASGCT): Dawn of a New Age?: In Vivo Gene Therapy
Scientific Track
Wednesday, Feb. 12, 10:30 a.m.-noon
Ballroom A

 

Hailey Sappington
Presentation: Mental Health Tips for Research Coordinators
BMT CTN Coordinators Track
Wednesday, Feb. 12, 10:45-11:15 a.m.
Room 316 ABC

 

John DiPersio, MD, PhD
Presentation: NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Scientific Track
Wednesday, Feb. 12, 3:30-3:45 p.m.
Ballroom B

 

Thursday, Feb. 13

Poster Presentations – All posters will be shown Thursday, Feb. 13, from 6:45-7:45 p.m. in Exhibit Hall 3.

 

Julianne Bailey, BSN, RN, OCN
Poster Abstract: An Academic Center’s Approach to REMS Revisions for Commercial CAR T Products
Poster Session: Administration Nursing Abstracts
Poster ID: 624

 

Todd Fehniger, MD, PhD
Poster Abstract: Combination Strategies Enhance NK Cell Therapy for Multiple Myeloma (MM): Memory-like Differentiation, NKG2A Blockade, and Improved Recognition Via BCMA CAR or MM-Targeting Antibodies
Poster Session: Engineered Immune Cells (CAR-T, NK, TCR): Basic/Preclinical – Antigen Finding, Safety
Poster ID: 271

 

Danielle Gagne, MBA, BSN, RN, BMTCN
Poster Abstract: Outpatient Transplant Coordinator Education Binder
Poster Session: Education Nursing Abstracts
Poster ID: 703

 

Armin Ghobadi, MD
Poster Abstract: Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein–Barr Virus–Driven Posttransplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy
Poster Session: Infectious Diseases and Cytotoxic T Lymphocytes
Poster ID: 742

 

Thomas Pfeiffer, MD

Poster Abstract: Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As a Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity
Poster Session: Conditioning Regimens
Poster ID: 235

 

Rahul Ramaswamy, MD
Poster Abstract: Waning Long Term Efficacy of COVID-19 Post-Transplant Vaccination for Prevention of COVID-19 Adverse Events in Transplant and Cellular Therapy (TCT) Patients
Poster Session: Immune Reconstitution and Immunobiology
Poster ID: 460

 

Ashley Rumsey, MSN, APRN, AGCNS-BC, OCN, BMTCN (with Chris Rimkus, RN, MSN, AOCN)
Poster Abstract: Practice Guideline Successes and Challenges: Update on the Cellular Infusion Practice Guideline
Poster Session: Clinical Nursing Abstracts
Poster ID: 642

 

Ashley Rumsey, MSN, APRN, AGCNS-BC, OCN, BMTCN
Poster Abstract: Statseal Hemostatic Powder in Hematologic Malignancies
Poster Session: Clinical Nursing Abstracts
Poster ID: 671

 

Robin Schultz, MBA, BSN, RN, BMTCN, OCN
Poster Abstract: The Suitability Review Process Development, Modification and Its Implications on Survival
Poster Session: Research Nursing Abstracts
Poster ID: 716

 

Jenna Williams, RN, MSN, AGNP-C
Poster Abstract: Initiation of Colony Stimulation Factors Following Autologous Hematopoietic Stem Cell Transplant: Do 2 Days Really Matter?
Poster Session: Clinical Nursing Abstracts
Poster ID: 654

 

Friday, Feb. 14

Parmeshwar N. Amatya, PhD, MPH
Presentation: Mechanism of CRS: Critical Roles of IFN-γ, CD40L, and CD4 Cells
Scientific Track
Friday, Feb. 14, 9-9:15 a.m.
Ballroom B

 

Ashley Rumsey, MSN, APRN, AGCNS-BC, OCN, BMTCN
Presentation: Nursing SIG & ASTCT Infusion Practice Guideline Updates
Nursing Track
Friday, Feb. 14, 9:30-9:45 a.m.
Room 316 ABC

 

Saturday, Feb. 15

Ling Huang and John DiPersio, MD, PhD
Presentation: Outcome Following CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplant: A Single Institution Experience
Scientific Track
Saturday, Feb. 15, 11:15-11:30 a.m.
Ballroom B

 

John DiPersio, MD, PhD
Presentation: A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloi
Scientific Track
Saturday, Feb. 15, 11:45 a.m.-noon
Ballroom A